Your Article Summary
See Latest ArticlesTopotecan combined with carboplatin in recurrent epithelial ovarian cancer: Results of a single-institutional phase II study
Gynecologic Oncology, 06/30/09
Kang H et al. - The relative high-dose of topotecan combined with carboplatin was feasible and produced modest activity in recurrent or persistent EOC. The RR and survival data appear promising for the initially platinum-sensitive cohort and thus this regimen may be considered for further development in this patient.
Related Articles
Topotecan triggers apoptosis in p53-deficient cells by forcing degradation of XIAP and survivin thereby activating caspase-3 mediated Bid cleavage
Journal of Pharmacology and Experimental Therapeutics, 10/14/09
Relevance Score: 82%
Combination of cladribine plus topotecan for recurrent or refractory pediatric acute myeloid leukemia
Cancer, 11/06/09
Relevance Score: 80%
Gefitinib in combination with oral topotecan and cyclophosphamide in relapsed neuroblastoma: Pharmacological rationale and clinical response
Pediatric Blood & Cancer, 10/27/09
Relevance Score: 80%
Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: childrens oncology group study d9803
Journal of Clinical Oncology, 10/08/09
Relevance Score: 80%
Today in Gynecologic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Semiquantitative assessment of the microdistribution of fluorescence-labeled monoclonal antibody in small peritoneal disseminations of ovarian cancer
Cancer Science, 12/10/09
MiR-15a and MiR-16 Control Bmi-1 Expression in Ovarian Cancer
Cancer Research, 12/10/09
Epigenetic Repression of microRNA-129-2 Leads to Overexpression of SOX4 Oncogene in Endometrial Cancer
Cancer Research, 12/10/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
18FDG-PET-CT in the follow-up of non-small cell lung cancer patients after radical radiotherapy with or without chemotherapy: An economic evaluation
European Journal of Cancer, 12/10/09
MicroRNAs: Predictors and modifiers of chemo- and radiotherapy in different tumour types
European Journal of Cancer, 12/10/09
Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies
European Journal of Cancer, 12/10/09